Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Hepatology ; (12): 349-351, 2008.
Artigo em Chinês | WPRIM | ID: wpr-332237

RESUMO

<p><b>OBJECTIVE</b>To investigate the efficacy and safety of adefovir dipivoxil (ADV) in treating hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis.</p><p><b>METHODS</b>Six hepatic cirrhosis (Child-Pugh A grade, liver function compensated) patients complicated with hepatitis B virus associated glomerulonephritis diagnosed by renal biopsy, real time PCR and urinary protein tests were treated with ADV for one year in addition to a routine treatment. The dosage of ADV was 100mg daily.</p><p><b>RESULTS</b>After 3 and 6 months treatment the negative conversion rates of HBV-DNA were 33.3% and 83.3%; the negative conversion rates of HBeAg were 16.7% and 66.7%; the positive conversion rates of HBeAb were both 16.7%; the recovery rates of ALT were 83.3% and 100.0%; and the recovery rates of TBil were 66.7% and 83.3% respectively. Protein in the urine of two patients was decreased to 0.3 g/d and in three patients it was 50% of the original values. After 1 year treatment the disease subsided fully in 3 and partially in 2 patients.</p><p><b>CONCLUSION</b>Treating hepatic cirrhosis complicated with hepatitis B virus associated glomerulonephritis using adefovir dipivoxil is effective and safe.</p>


Assuntos
Adolescente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Adenina , Usos Terapêuticos , Antivirais , Usos Terapêuticos , Glomerulonefrite , Tratamento Farmacológico , Virologia , Hepatite B , Tratamento Farmacológico , Vírus da Hepatite B , Cirrose Hepática , Tratamento Farmacológico , Virologia , Organofosfonatos , Usos Terapêuticos
2.
Chinese Journal of Pathology ; (12): 788-790, 2005.
Artigo em Chinês | WPRIM | ID: wpr-258259

RESUMO

<p><b>OBJECTIVE</b>To investigate the clinicopathologic features of gastrointestinal stromal tumors (GISTs) and to identify reliable prognostic parameters.</p><p><b>METHODS</b>Fifty-nine GISTs were studied by immunostaining of CD117, CD34, SMA, desmin, S-100, bcl-2, and Ki-67. Histopathologic evaluations included tumor size, necrosis, histological growth patterns, mitotic activities and tumor lymphocytic infiltrate. The patients were clinically followed for 2 to 9 years. Univariate, multivariate and correlative statistical evaluations were used to analyze the data.</p><p><b>RESULTS</b>Among the 59 patients, 40 were alive and 15 died of their tumors at follow-up, the remaining 4 patients died of other causes. Pathological parameters that correlated with prognosis included tumor sizes of more than 5 cm, tumor tissue necrosis, mitotic cell count equal or higher than 5 per 50 high power field, Ki-67 labeling index (LI) equal or higher than 5% and intense bcl-2 immunostaining. Multivariate analysis showed that the mitotic count and Ki-67 LI were independent prognostic indicators. There was a correlation between mitotic count and Ki-67 LI.</p><p><b>CONCLUSIONS</b>Mitotic count and Ki-67 LI are the best predictors for a poor outcome of GIST after surgical treatment. Ki-67 immunostaining may substitute mitotic count as a useful prognostic parameter.</p>


Assuntos
Adolescente , Adulto , Idoso , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Ciclina D1 , Metabolismo , Seguimentos , Tumores do Estroma Gastrointestinal , Metabolismo , Patologia , Antígeno Ki-67 , Metabolismo , Prognóstico , Proteínas Proto-Oncogênicas c-bcl-2 , Metabolismo , Proteínas Proto-Oncogênicas c-kit , Metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA